{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:33:00Z","timestamp":1788543180208,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22bm0804006h0006"],"award-info":[{"award-number":["22bm0804006h0006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease characterized by progressive heterotopic ossification (HO) in soft tissues due to a heterozygous mutation of the ACVR1A gene (FOP-ACVR1A), which erroneously transduces the BMP signal by Activin-A. Although inflammation is known to trigger HO in FOP, the role of FOP-ACVR1A on inflammatory cells remains to be elucidated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We generated immortalized monocytic cell lines from FOP-iPSCs (FOP-ML) and mutation rescued iPSCs (resFOP-ML). Cell morphology was evaluated during the monocyte induction and after immortalization. Fluorescence-activated cell sorting (FACS) was performed to evaluate the cell surface markers CD14 and CD16 on MLs. MLs were stimulated with lipopolysaccharide or Activin-A and the gene expression was evaluated by quantitative PCR and microarray analysis. Histological analysis was performed for HO tissue obtained from wild type mice and FOP-ACVR1A mice which conditionally express human mutant<jats:italic>ACVR1A<\/jats:italic>gene by doxycycline administration. Without any stimulation, FOP-ML showed the pro-inflammatory signature of CD16+\u2009monocytes with an upregulation of<jats:italic>INHBA<\/jats:italic>gene, and treatment of resFOP-ML with Activin-A induced an expression profile mimicking that of FOP-ML at baseline. Treatment of FOP-ML with Activin-A further induced the inflammatory profile with an up-regulation of inflammation-associated genes, of which some, but not all, of which were suppressed by corticosteroid. Experiments using an inhibitor for TGF\u03b2 or BMP signal demonstrated that Activin-A-induced genes such as<jats:italic>CD16<\/jats:italic>and<jats:italic>CCL7<\/jats:italic>, were regulated by both signals, indicating Activin-A transduced dual signals in FOP-ML. A comparison with resFOP-ML identified several down-regulated genes in FOP-ML including<jats:italic>LYVE-1<\/jats:italic>, which is known to suppress matrix-formation in vivo. The down-regulation of LYVE-1 in HO tissues was confirmed in FOP model mice, verifying the significance of the in vitro experiments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results indicate that FOP-ML faithfully recapitulated the phenotype of primary monocytes of FOP and the combination with resFOP-ML is a useful tool to investigate molecular events at the initial inflammation stage of HO in FOP.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13023-022-02506-3","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T12:04:04Z","timestamp":1663761844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs"],"prefix":"10.1186","volume":"17","author":[{"given":"Hirotsugu","family":"Maekawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kamakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yoshitomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumu K.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0184-9685","authenticated-orcid":false,"given":"Junya","family":"Toguchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"2506_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.bone.2008.05.013","volume":"43","author":"EM Shore","year":"2008","unstructured":"Shore EM, Kaplan FS. Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone. 2008;43:427\u201333.","journal-title":"Bone"},{"key":"2506_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38:525\u20137.","journal-title":"Nat Genet"},{"key":"2506_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/humu.20868","volume":"30","author":"FS Kaplan","year":"2009","unstructured":"Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009;30:379\u201390.","journal-title":"Hum Mutat"},{"key":"2506_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1385\/BMM:3:3-4:195","volume":"3","author":"RJ Pignolo","year":"2005","unstructured":"Pignolo RJ, Suda RK, Kaplan FS. The fibrodysplasia ossificans progressive lesion. Clin Rev Bone Miner Metabol. 2005;3:195\u2013200.","journal-title":"Clin Rev Bone Miner Metabol"},{"key":"2506_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.2728","volume":"31","author":"RJ Pignolo","year":"2016","unstructured":"Pignolo RJ, Bedford-Gay C, Liljesthr\u00f6m M, et al. The natural history of flare-ups in Fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31:650\u20136.","journal-title":"J Bone Miner Res"},{"key":"2506_CR6","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1002\/stem.1981","volume":"33","author":"Y Matsumoto","year":"2015","unstructured":"Matsumoto Y, Ikeya M, Hino K, et al. New protocol to optimize iPS cells for genome analysis of Fibrodysplasia ossificans progressiva. Stem Cells. 2015;33:1730\u201342.","journal-title":"Stem Cells"},{"key":"2506_CR7","doi-asserted-by":"publisher","first-page":"15438","DOI":"10.1073\/pnas.1510540112","volume":"112","author":"K Hino","year":"2015","unstructured":"Hino K, Ikeya M, Horigome K, et al. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci U S A. 2015;112:15438\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2506_CR8","doi-asserted-by":"publisher","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","volume":"7","author":"SJ Hatsell","year":"2015","unstructured":"Hatsell SJ, Idone V, Wolken DM, et al. ACVR1R206H receptor mutation causes Fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. 2015;7:303ra137.","journal-title":"Sci Transl Med"},{"key":"2506_CR9","doi-asserted-by":"publisher","first-page":"95042","DOI":"10.1172\/jci.insight.95042","volume":"6","author":"E Williams","year":"2021","unstructured":"Williams E, Bagarova J, Kerr G, et al. Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight. 2021;6:95042.","journal-title":"JCI Insight"},{"key":"2506_CR10","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1172\/JCI93521","volume":"127","author":"K Hino","year":"2017","unstructured":"Hino K, Horigome K, Nishio M, et al. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva. J Clin Invest. 2017;127:3339\u201352.","journal-title":"J Clin Invest"},{"key":"2506_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cytogfr.2009.02.007","volume":"20","author":"DJ Phillips","year":"2009","unstructured":"Phillips DJ, de Kretser DM, Hedger MP. Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev. 2009;20:153\u201364.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2506_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/jbmr.3304","volume":"33","author":"MR Convente","year":"2018","unstructured":"Convente MR, Chakkalakal SA, Yang EJ, et al. Depletion of mast cells and macrophages impairs heterotopic ossification in an Acvr1R206H mouse model of Fibrodysplasia ossificans progressiva. J Bone Miner Res. 2018;33:269\u201382.","journal-title":"J Bone Miner Res"},{"key":"2506_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/cyto.b.21594","volume":"94","author":"G Del Zotto","year":"2018","unstructured":"Del Zotto G, Antonini F, Azzari I, et al. Peripheral blood mononuclear cell immunophenotyping in Fibrodysplasia ossificans progressiva patients: evidence for monocyte DNAM1 Up-regulation. Cytometry B Clin Cytom. 2018;94:613\u201322.","journal-title":"Cytometry B Clin Cytom"},{"key":"2506_CR14","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1359\/jbmr.060215","volume":"21","author":"JL Fiori","year":"2006","unstructured":"Fiori JL, Billings PC, de la Pe\u00f1a LS, et al. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res. 2006;21:902\u20139.","journal-title":"J Bone Miner Res"},{"key":"2506_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122958","volume":"3","author":"E Barruet","year":"2018","unstructured":"Barruet E, Morales BM, Cain CJ, et al. NF-\u03baB\/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight. 2018;3: e122958.","journal-title":"JCI Insight"},{"key":"2506_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/1750-1172-8-190","volume":"8","author":"Y Matsumoto","year":"2013","unstructured":"Matsumoto Y, Hayashi Y, Schlieve CR, et al. Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet J Rare Dis. 2013;8:190.","journal-title":"Orphanet J Rare Dis"},{"key":"2506_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059243","volume":"8","author":"MD Yanagimachi","year":"2013","unstructured":"Yanagimachi MD, Niwa A, Tanaka T, et al. Robust and highly-efficient differentiation of functional monocytic cells from human pluripotent stem cells under serum- and feeder cell-free conditions. PLoS ONE. 2013;8: e59243.","journal-title":"PLoS ONE"},{"key":"2506_CR18","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.humimm.2013.05.017","volume":"4","author":"M Haruta","year":"2013","unstructured":"Haruta M, Tomita Y, Imamura Y, et al. Generation of a large number of functional dendritic cells from human monocytes expanded by forced expression of cMYC plus BMI1. Hum Immunol. 2013;4:1400\u20138.","journal-title":"Hum Immunol"},{"key":"2506_CR19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/art.39960","volume":"69","author":"Y Kawasaki","year":"2017","unstructured":"Kawasaki Y, Oda H, Ito J, et al. Identification of a high-frequency somatic NLRC4 mutation as a cause of autoinflammation by pluripotent cell-based phenotype dissection. Arthritis Rheumatol. 2017;69:447\u201359.","journal-title":"Arthritis Rheumatol"},{"key":"2506_CR20","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.stemcr.2018.04.004","volume":"10","author":"F Honda-Ozaki","year":"2018","unstructured":"Honda-Ozaki F, Terashima M, Niwa A, et al. Pluripotent stem cell model of Nakajo-Nishimura syndrome untangles proinflammatory pathways mediated by oxidative stress. Stem Cell Reports. 2018;10:1835\u201350.","journal-title":"Stem Cell Reports"},{"key":"2506_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13023-020-01406-8","volume":"15","author":"H Maekawa","year":"2020","unstructured":"Maekawa H, Kawai S, Nishio M, et al. Prophylactic treatment of rapamycin ameliorates naturally developing and episode -induced heterotopic ossification in mice expressing human mutant ACVR1. Orphanet J Rare Dis. 2020;15:122.","journal-title":"Orphanet J Rare Dis"},{"key":"2506_CR22","doi-asserted-by":"publisher","first-page":"eaay9526","DOI":"10.1126\/sciadv.aay9526","volume":"6","author":"Y Chen","year":"2020","unstructured":"Chen Y, Shen W, Tang C, et al. Targeted pathological collagen delivery of sustained-release rapamycin to prevent heterotopic ossification. Sci Adv. 2020;6:eaay9526.","journal-title":"Sci Adv"},{"key":"2506_CR23","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1182\/bloodadvances.2018020123","volume":"2","author":"VS Wacleche","year":"2018","unstructured":"Wacleche VS, Cattin A, Goulet JP, et al. CD16(+) monocytes give rise to CD103(+)RALDH2(+)TCF4(+) dendritic cells with unique transcriptional and immunological features. Blood Adv. 2018;2:2862\u201378.","journal-title":"Blood Adv"},{"key":"2506_CR24","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3390\/ijms20123107","volume":"20","author":"M Aristorena","year":"2019","unstructured":"Aristorena M, Gallardo-Vara E, Vicen M, et al. MMP-12, secreted by pro-inflammatory macrophages, targets endoglin in human macrophages and endothelial cells. J Mol Sci. 2019;20:3107.","journal-title":"J Mol Sci"},{"key":"2506_CR25","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1111\/bph.12681","volume":"171","author":"SP Yun","year":"2014","unstructured":"Yun SP, Lee SJ, Oh SY, et al. Reactive oxygen species induce MMP12-dependent degradation of collagen 5 and fibronectin to promote the motility of human umbilical cord-derived mesenchymal stem cells. Br J Pharmacol. 2014;171:3283\u201397.","journal-title":"Br J Pharmacol"},{"key":"2506_CR26","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720\u201332.","journal-title":"Blood"},{"key":"2506_CR27","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.molimm.2011.04.019","volume":"48","author":"GT Lee","year":"2011","unstructured":"Lee GT, Jung YS, Lee J-H, et al. Bone morphogenetic protein 6-induced interleukin-1\u03b2 expression in macrophages requires PU.1\/Smad1 interaction. Mol Immunol. 2011;48:1540\u20137.","journal-title":"Mol Immunol"},{"key":"2506_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cellimm.2014.02.008","volume":"291","author":"RL Terry","year":"2014","unstructured":"Terry RL, Miller SD. Molecular control of monocyte development. Cell Immunol. 2014;291:16\u201321.","journal-title":"Cell Immunol"},{"key":"2506_CR29","volume":"2009","author":"K Inoue","year":"2009","unstructured":"Inoue K, Takano H, Shimada A, et al. Metallothionein as an anti-inflammatory mediator. Mediators Inflamm. 2009;2009: 101659.","journal-title":"Mediators Inflamm"},{"key":"2506_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.cell.2011.08.050","volume":"147","author":"AC Mullen","year":"2011","unstructured":"Mullen AC, Orlando DA, Newman JJ, et al. Master transcription factors determine cell-type-specific responses to TGF-beta signaling. Cell. 2011;147:565\u201376.","journal-title":"Cell"},{"key":"2506_CR31","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3892\/mmr.2015.3459","volume":"12","author":"S Takahashi","year":"2015","unstructured":"Takahashi S. Positive and negative regulators of the metallothionein gene (Review). Mol Med Rep. 2015;12:795\u20139.","journal-title":"Mol Med Rep"},{"key":"2506_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.cyto.2014.06.007","volume":"69","author":"JW Cheng","year":"2014","unstructured":"Cheng JW, Sadeghi Z, Levine AD, et al. The role of CXCL12 and CCL7 chemokines in immune regulation, embryonic development, and tissue regeneration. Cytokine. 2014;69:277\u201383.","journal-title":"Cytokine"},{"key":"2506_CR33","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.4049\/jimmunol.157.12.5613","volume":"157","author":"EA Garcia-Zepeda","year":"1996","unstructured":"Garcia-Zepeda EA, Combadiere C, Rothenberg ME, et al. Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J Immunol. 1996;157:5613\u201326.","journal-title":"J Immunol"},{"key":"2506_CR34","first-page":"1","volume":"1","author":"FS Kaplan","year":"2019","unstructured":"Kaplan FS, Al Mukaddam M, Baujat G, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Intl Clin Council FOP. 2019;1:1\u2013111.","journal-title":"Proc Intl Clin Council FOP"},{"key":"2506_CR35","doi-asserted-by":"publisher","first-page":"7029","DOI":"10.1073\/pnas.111145798","volume":"98","author":"TV Pestova","year":"2001","unstructured":"Pestova TV, Kolupaeva VG, Lomakin IB, et al. Molecular mechanisms of translation initiation in eukaryotes. Proc Natl Acad Sci U S A. 2001;98:7029\u201336.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2506_CR36","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.4161\/cc.9.20.13630","volume":"9","author":"D Shahbazian","year":"2010","unstructured":"Shahbazian D, Parsyan A, Petroulakis E, et al. eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle. 2010;9:4106\u20139.","journal-title":"Cell Cycle"},{"key":"2506_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF02737601","volume":"17","author":"JF Penrose","year":"1999","unstructured":"Penrose JF. LTC4 synthase. Enzymology, biochemistry, and molecular characterization. Clin Rev Allergy Immunol. 1999;17:133\u201352.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2506_CR38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/9780470033449.ch13","volume":"271","author":"KF Austen","year":"2005","unstructured":"Austen KF. The mast cell and the cysteinyl leukotrienes. Novartis Found Symp. 2005;271:166\u201375.","journal-title":"Novartis Found Symp"},{"key":"2506_CR39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejphar.2008.11.054","volume":"603","author":"K Ma","year":"2009","unstructured":"Ma K, Zhang Y, Zhu D, et al. Protective effects of asiatic acid against D-galactosamine\/lipopolysaccharide-induced hepatotoxicity in hepatocytes and kupffer cells co-cultured system via redox-regulated leukotriene C4 synthase expression pathway. Eur J Pharmacol. 2009;603:98\u2013107.","journal-title":"Eur J Pharmacol"},{"key":"2506_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.matbio.2018.02.001","volume":"78\u201379","author":"DG Jackson","year":"2019","unstructured":"Jackson DG. Hyaluronan in the lymphatics: the key role of the hyaluronan receptor LYVE-1 in leucocyte trafficking. Matrix Biol. 2019;78\u201379:219\u201335.","journal-title":"Matrix Biol"},{"key":"2506_CR41","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41467-019-14172-4","volume":"11","author":"M Sorkin","year":"2020","unstructured":"Sorkin M, Huber AK, Charles Hwang C, et al. Regulation of heterotopic ossification by monocytes in a mouse model of aberrant wound healing. Nat Commun. 2020;11:722.","journal-title":"Nat Commun"},{"key":"2506_CR42","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.immuni.2018.06.008","volume":"49","author":"HY Lim","year":"2018","unstructured":"Lim HY, Lim SY, Tan CK, et al. Hyaluronan receptor LYVE-1-expressing macrophages maintain arterial tone through Hyaluronan-mediated regulation of smooth muscle cell collagen. Immunity. 2018;49:326\u201341.","journal-title":"Immunity"},{"key":"2506_CR43","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2504","volume":"17","author":"G Tiscornia","year":"2011","unstructured":"Tiscornia G, Vivas EL, Belmonte JCI. Diseases in a dish: modeling human genetic disorders using induced pluripotent cells. Nat Med. 2011;17:1570\u20136.","journal-title":"Nat Med"},{"key":"2506_CR44","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/art.38912","volume":"67","author":"K Yokoyama","year":"2015","unstructured":"Yokoyama K, Ikeya M, Umeda K, et al. Enhanced chondrogenesis of iPS cells from neonatal-onset multisystem inflammatory disease occurs via the caspase-1-independent cAMP\/PKA\/CREB pathway. Arthritis Rheumatol. 2015;67:302\u201314.","journal-title":"Arthritis Rheumatol"},{"key":"2506_CR45","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41551-019-0410-7","volume":"3","author":"S Kawai","year":"2019","unstructured":"Kawai S, Yoshitomi H, Sunaga J, et al. In vitro bone-like nodules generated from patient-derived iPSCs recapitulate pathological bone phenotypes. Nat Biomed Eng. 2019;3:558\u201370.","journal-title":"Nat Biomed Eng"},{"key":"2506_CR46","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.stemcr.2021.01.014","volume":"16","author":"Y Pretemer","year":"2021","unstructured":"Pretemer Y, Kawai S, Nagata S, et al. Differentiation of hypertrophic chondrocytes from human iPSCs for the in vitro modeling of chondrodysplasias. Stem Cell Rep. 2021;16:610\u201325.","journal-title":"Stem Cell Rep"},{"key":"2506_CR47","doi-asserted-by":"publisher","first-page":"234e242","DOI":"10.1016\/j.alit.2017.08.008","volume":"67","author":"A Igarashi","year":"2018","unstructured":"Igarashi A, Ebihara Y, Kumagai T, et al. Mast cells derived from human induced pluripotent stem cells are useful for allergen tests. Allergol Int. 2018;67:234e242.","journal-title":"Allergol Int"},{"key":"2506_CR48","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, et al. NF-\u03baB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023.","journal-title":"Signal Transduct Target Ther"},{"key":"2506_CR49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2008.302","volume":"19","author":"X Guo","year":"2009","unstructured":"Guo X, Wang X-F. Signaling cross-talk between TGF-beta\/BMP and other pathways. Cell Res. 2009;19:71\u201388.","journal-title":"Cell Res"},{"key":"2506_CR50","doi-asserted-by":"publisher","first-page":"116129","DOI":"10.1016\/j.bone.2021.116129","volume":"153","author":"K Matsuo","year":"2021","unstructured":"Matsuo K, Lepinski A, Chavez RD, et al. ACVR1 R206H extends inflammatory responses in human induced pluripotent stem cell-derived macrophages. Bone. 2021;153:116129.","journal-title":"Bone"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02506-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02506-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02506-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T09:32:32Z","timestamp":1701077552000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02506-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2506"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02506-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols dealing with human subjects were approved by the ethics committee of the Department of Medicine and Graduate School of Medicine of Kyoto University. Written informed consent was provided by each donor. All animal experiments were approved by the institutional animal committee of Kyoto University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was provided by each donor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"364"}}